The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Great news ;)
This is where the tumbleweed gif goes, right?
That’s the problem. Right?
I don't want them to "return shareholder value" at this stage, I want them to build it - which they are doing admirably. Christmas bonuses all round.
From a consumer point of view it sounds fair though. The whole point of a *windfall* tax is to share around the *excess* profit that’s an unplanned and unbudgeted product of circumstances. As both a shareholder and a consumer I feel conflicted but listening to the interview on Today I couldn’t help but think he was being a bit disingenuous, and he wasn’t even pressed on that specific point. Anyway as he said the devil will be in the emerging detail; SSE have certainly been doing a decent job of getting their message across, given that most consumers lump all energy producing and distribution companies into the same evil boat with no idea how it all works.
That says it’s not the number of panels as such that is the issue: “For DNO permission, the system approval is based on the rating of the inverter. Prior permission is not needed for systems with an inverter up to or under 3.68kW for a single phase supply or 11.04kW for a three phase supply, as you will be generating at or below 16A per phase.”. Anyway, interesting but rather off topic!
Yes we were just quoted - for installing 8 panels (small useable roof area) - but @ 400W.
Precisely the opposite of what Starmer said, which was why buy someone else’s company when you can start your own. Plenty of wind to go around.
*operators*
The article you linked to is about storage *operatirs*. It says: “ The operators are able to benefit from the surge in electricity prices, which are seen by the marginal cost of the last generating unit turned on to meet demand, which is usually a gas-fired plant. At the same time, they have largely escaped the rising commodity costs hitting the companies that actually make the batteries.”
Hmmm
I have a recurring order for porridge direct with Opti. They were unable to deliver the latest because it was “out of stock “. GoFigure.
Is that the biolabs where the Gates-Soros nanobots are manufactured for Hunter Biden? Top entertainment, this thread. Go on, do the one about the fake Moon landings. I'll get the popcorn.
Unless things have changed it's in Suzhou in Jiangsu. I'm not aware of any current lockdown status.
This. I've been mentioning flow batteries whenever I get the chance, on social media, for this very reason. People aren't aware of the potential.
Two years of testing shows why things seem sometimes to move very slowly - but hugely significant validation.
I've been reviewing my holding, while still 27% up. I was just reading some of the reviews on Trustpilot https://uk.trustpilot.com/review/axisbiotix.com which I presume have to be from bona fide customers. It's clear that, as we already know, Axisbiotix doesn't work for everyone. It's also clear that it's life changing for many. But two words leapt out at me that were volunteered by reviewers: acne (perhaps an obvious natural extension) - and arthritis pain. Huge.
The chip shortage looks like getting worse, too, as a result of the war in Ukraine (neon supply). Reluctantly just sold my holding at a small loss. I've been in and out of XPP for years and it's a good company, so I might be back, but avoiding for now. Hope to be proved wrong!
It pre-dates that. RNS Number : 6096S, SSE PLC, 17 November 2021: SSE'S NET ZERO ACCELERATION PROGRAMME (including, inter alia):
"Growth-enabling dividend, paying at least £3.50 per share across the five years, comprising:
o completion of current RPI linked dividend plan to March 2023
o followed by a rebased dividend to 60p in 23/24 with attractive annual growth of at least 5% to March 2026
o scrip dividend option capped at 25%".
Very sound. The seaweed project is fascinating. More to follow.
He's been in for ages and has made similar pronouncements before, but he does remain very bullish on the numbers.